270 related articles for article (PubMed ID: 23540512)
21. Morphine to methadone conversion: an interpretation of published data.
Pollock AB; Tegeler ML; Morgan V; Baumrucker SJ
Am J Hosp Palliat Care; 2011 Mar; 28(2):135-40. PubMed ID: 20555039
[TBL] [Abstract][Full Text] [Related]
22. Outcome of opioid switching 4 weeks after discharge from a palliative care unit.
Mercadante S; Ferrera P; Casuccio A
Curr Med Res Opin; 2011 Dec; 27(12):2357-60. PubMed ID: 22029619
[TBL] [Abstract][Full Text] [Related]
23. Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States.
Neil N; Merchant S; Provenzano D; Ogden K; Mody SH
J Med Econ; 2013; 16(2):307-17. PubMed ID: 23216013
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.
Ikenberg R; Hertel N; Moore RA; Obradovic M; Baxter G; Conway P; Liedgens H
J Med Econ; 2012; 15(4):724-36. PubMed ID: 22364286
[TBL] [Abstract][Full Text] [Related]
25. Opioid switching in patients with advanced cancer followed at home. A retrospective analysis.
Mercadante S; Valle A; Porzio G; Fusco F; Aielli F; Adile C; Casuccio A;
J Pain Symptom Manage; 2013 Feb; 45(2):298-304. PubMed ID: 23102561
[TBL] [Abstract][Full Text] [Related]
26. Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists.
Schwittay A; Schumann C; Litzenburger BC; Schwenke K
J Pain Palliat Care Pharmacother; 2013 Aug; 27(3):225-34. PubMed ID: 23957433
[TBL] [Abstract][Full Text] [Related]
27. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?
Ripamonti C; Groff L; Brunelli C; Polastri D; Stavrakis A; De Conno F
J Clin Oncol; 1998 Oct; 16(10):3216-21. PubMed ID: 9779694
[TBL] [Abstract][Full Text] [Related]
28. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.
Hartrick CT; Rozek RJ
CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608
[TBL] [Abstract][Full Text] [Related]
29. Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model.
Ono H; Nakamura A; Kanbara T; Minami K; Shinohara S; Sakaguchi G; Kanemasa T
J Pharmacol Sci; 2014; 125(3):264-73. PubMed ID: 24965165
[TBL] [Abstract][Full Text] [Related]
30. Therapy switching in patients receiving long-acting opioids.
Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
[TBL] [Abstract][Full Text] [Related]
31. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids.
Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; David F; Mangione S
Clin J Pain; 2007; 23(9):793-8. PubMed ID: 18075407
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
33. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
O'Connor AB; Zwemer FL; Hays DP; Feng C
Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
[TBL] [Abstract][Full Text] [Related]
34. Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules.
Webster LR; Brewer R; Morris D; Cleveland JM; Setnik B
Postgrad Med; 2011 Sep; 123(5):155-64. PubMed ID: 21904098
[TBL] [Abstract][Full Text] [Related]
35. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
36. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses.
Svendsen K; Borchgrevink P; Fredheim O; Hamunen K; Mellbye A; Dale O
Palliat Med; 2011 Oct; 25(7):725-32. PubMed ID: 21378066
[TBL] [Abstract][Full Text] [Related]
37. A Randomized Controlled Trial on the Effect of Tapentadol and Morphine on Conditioned Pain Modulation in Healthy Volunteers.
Martini C; van Velzen M; Drewes A; Aarts L; Dahan A; Niesters M
PLoS One; 2015; 10(6):e0128997. PubMed ID: 26076171
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
Afilalo M; Morlion B
Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
[TBL] [Abstract][Full Text] [Related]
39. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
[TBL] [Abstract][Full Text] [Related]
40. The use of opioids in the last week of life in an acute palliative care unit.
Mercadante S; Ferrera P; Casuccio A
Am J Hosp Palliat Care; 2010 Dec; 27(8):514-7. PubMed ID: 20439486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
